A venture capital firm is focused on early-stage ventures and has raised multiple funds since inception. The firm primarily makes equity investments, with total capital deployed per company typically ranging from $250K to $5M over the life of the investment and initial checks generally between $100K and $500K. The firm prefers to invest in companies located on the U.S. West Coast but remains open to opportunities across North America. The firm maintains long-standing relationships with several Japanese medical technology corporations and seeks opportunities that may be introduced into the Japanese market.
The firm targets Seed and early-stage medical device companies, with particular interest in single-use therapeutic devices. The firm prefers opportunities with a 510(k) regulatory pathway but will also consider PMA applications. Areas of strongest interest include interventional cardiovascular and neurovascular devices, minimally invasive surgical instrumentation, and novel therapeutic medical device technologies. The firm remains open to evaluating other device categories and indications on a case-by-case basis.
From a company and management team perspective, the firm values professionalism and is willing to work with companies that do not yet have a fully built-out management team. The firm does not always require a board seat but seeks to add strategic value, particularly by facilitating corporate partnerships in Japan when appropriate.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 